Back to top
more

Halozyme Therapeutics, Inc. (HALO)

(Delayed Data from NSDQ)

$19.97 USD

19.97
1,589,794

-0.16 (-0.79%)

Updated Jan 17, 2020 03:56 PM ET

Add to portfolio

3-Hold     3    

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.66%
17.94%
9.57%
5.30%
2.19%
10.75%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

D Value | F Growth | A Momentum | F VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

Why Is Halozyme Therapeutics (HALO) Up 6.1% Since Last Earnings Report?

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

HALO

Zacks Equity Research

Halozyme Therapeutics (HALO) Looks Good: Stock Adds 5.4% in Session

Halozyme Therapeutics (HALO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

ANIK HALO

Zacks Equity Research

Halozyme (HALO) Earnings & Revenues Miss Estimates in Q3

Halozyme (HALO) reports lower-than-expected earnings and revenues in third-quarter 2019. It lowers the sales outlook for 2019 and raises the same for operating expenses.

JNJ RHHBY HALO TAK

Zacks Equity Research

Halozyme Therapeutics (HALO) Reports Q3 Loss, Misses Revenue Estimates

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of -41.67% and -21.40%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

HALO

Zacks Equity Research

Halozyme Therapeutics (HALO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HALO

Zacks Equity Research

Roche's New Perjeta Combo Meets Goal in Breast Cancer Study

Roche's (RHHBY) new fixed-dose combination of Perjeta and Herceptin meets the primary endpoint in the phase III study for treating patients with HER2-positive early breast cancer.

MRK RHHBY PBYI HALO

Zacks Equity Research

Halozyme Therapeutics (HALO) Reports Q2 Loss, Lags Revenue Estimates

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 41.18% and -0.94%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

HALO

Zacks Equity Research

Earnings Preview: Halozyme Therapeutics (HALO) Q2 Earnings Expected to Decline

Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HALO

Zacks Equity Research

Alexion (ALXN) to Report Q2 Earnings: What's in the Cards?

Soliris' solid performance is likely to reflect in Alexion's (ALXN) second-quarter 2019 results.

REGN ALXN GILD HALO

Zacks Equity Research

Alexion (ALXN) Stock Up 30.7% YTD: Will the Momentum Stay?

Alexion (ALXN) gains 30.7% on solid performance of lead drug Soliris and approval of Ultomiris.

GILD CELG HALO ALXN

Zacks Equity Research

Halozyme Therapeutics (HALO) Matches Q1 Earnings Estimates

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 0.00% and -20.23%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

HALO

Zacks Equity Research

Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?

Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HALO

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for March 4th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 4th

TARO HALO DLHC CRMT

Zacks Equity Research

Halozyme Therapeutics (HALO) Reports Q4 Loss, Tops Revenue Estimates

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 50.00% and 1.65%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

HALO

Zacks Equity Research

Analysts Estimate Halozyme Therapeutics (HALO) to Report a Decline in Earnings: What to Look Out for

Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HALO

Zacks Equity Research

Alexion's (ALXN) Earnings Beat Estimates in Q4, Shares Up

Alexion (ALXN) exceeds earnings and sales estimates in the fourth quarter of 2018 on strong performance by Soliris.

ACHN HALO ALXN AKTX

Zacks Equity Research

Alexion (ALXN) to Report Q4 Earnings: What's in the Cards?

Alexion's key drug like Soliris should drive growth in the fourth quarter of 2018.

REGN ALXN HALO BHC

Zacks Equity Research

Alexion's Ultomiris Meets Primary Endpoint in aHUS Study

Alexion's (ALXN) Ultomiris meets primary endpoint in a phase III study conducted on complement inhibitor-naive patients with aHUS.

ACHN ALXN HALO AKTX

Zacks Equity Research

Alexion's (ALXN) Soliris Drives Growth Amid Pricing Pressure

Alexion (ALXN) drives growth on consistent demand for lead drug, Soliris. The label expansion of the drug should further propel sales and combat pricing pressure.

BMY ALXN HALO EXEL

Zacks Equity Research

Alexion's Ultomiris Gets Early FDA Nod for Rare Blood Disorder

Alexion (ALXN) wins an FDA approval for Ultomiris to treat adult patients with paroxysmal nocturnal hemoglobinuria. The approval comes way before the original action date of Feb 18, 2019.

GILD ALXN HALO ANIK

Zacks Equity Research

Halozyme Therapeutics Sees Hammer Chart Pattern: Time to Buy?

Halozyme Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.

HALO

Zacks Equity Research

Halozyme Therapeutics (HALO) Reports Q3 Loss, Misses Revenue Estimates

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 17.39% and -17.20%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

HALO

Zacks Equity Research

Earnings Preview: Halozyme Therapeutics (HALO) Q3 Earnings Expected to Decline

Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HALO

Zacks Equity Research

Alexion's (ALXN) Earnings Beat Estimates in Q3, Guidance Up

Alexion (ALXN) beats earnings estimates and marginally misses sales estimates in the third quarter of 2018. The company also inks a deal to acquire Syntimmune for $1.2 billion.

GILD HALO ALXN CRSP

Zacks Equity Research

Halozyme Therapeutics (HALO) Reports Q2 Loss, Tops Revenue Estimates

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 27.27% and 11.79%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

HALO